Next generation HPC/QC in silico drug discovery platform for de novo designbroad
ATLAS · Horizon Europe grant · 2022-09-01–2024-08-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATORCHALLENGES-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01. CORDIS record →
Objective
ATLAS is a powerful in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing. The platform is the result of decades of research by leading experts in molecular dynamics. The technology is grounded on over 100 peer-reviewed papers and two ERC grants. Our beta code has gathered important accolades like the prestigious ATOS-Joseph Fourier prize and first place at the foremost rational drug design competitionthe SAMPL challenge. ATLAS can replace costly and laborious experiments. It can even run entire drug discovery campaigns in silico, reducing cycle times and cost by at least 50%. By 2027, we will have a 35-project portfolio, and the first ATLAS-generated compound will reach the clinic. Thereafter, our objective is to generate a new candidate every 18 months. That year, our team will surpass 50 people and well expand into the US market. We aim at securing a leadership position in the nascent in-silico drug discovery market.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| QUBIT PHARMACEUTICALS | FR | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.